Business Context and Reporting Period
This Form 8-K was filed by Chemomab Therapeutics Ltd. (formerly Anchiano Therapeutics Ltd.) on April 5, 2021. The report details an amendment to an Asset Purchase and Assignment Agreement entered into on March 16, 2021, between the Company's wholly-owned subsidiary, Anchiano Therapeutics Inc., and Kestrel Therapeutics, Inc.
Key Financial Metrics
The filing discloses specific transaction values related to the asset sale but does not provide comprehensive financial statements, revenue, profit, cash flow, or debt metrics for the reporting period.
- Total Transaction Value: $1,000,000
- Initial Non-Refundable Payment: $125,000 (paid February 2, 2021)
- Second Upfront Payment: $125,000 (due by April 5, 2021)
- Remaining Balance: $750,000 (due at Closing)
Material Changes
On March 31, 2021, the parties amended the original agreement to clarify the payment schedule and conditions for effectiveness:
- Kestrel Therapeutics agreed to pay an additional non-refundable upfront payment of $125,000 by April 5, 2021.
- The remaining $750,000 is scheduled to be paid at Closing, defined as occurring on or before April 30, 2021.
- The amendment's terms and obligations are contingent upon the receipt of the Second Upfront Payment by the April 5, 2021 deadline.
Outlook, Risks, and Contingencies
The filing highlights a material contingency: the effectiveness of the amended agreement is strictly dependent on Kestrel Therapeutics delivering the $125,000 Second Upfront Payment by April 5, 2021. If this payment is not received by the deadline, the terms of the amendment do not become effective. The transaction involves the sale of rights and obligations related to the research, development, and commercialization of specific Compounds and Products.
Investor Verification Checklist
- Confirm whether the $125,000 Second Upfront Payment was received by Kestrel Therapeutics by the April 5, 2021 deadline.
- Verify the status of the Closing and the subsequent payment of the remaining $750,000 by April 30, 2021.
- Review the specific definitions of "Compounds and Products" in the underlying Collaboration and License Agreement to understand the scope of assets sold.
- Check for subsequent filings regarding the finalization of the asset transfer or any failure to meet the payment conditions.